Find generic entry opportunities
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Dispersible macromolecule compositions and methods for their preparation and use|
|Abstract:||A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly suitable for pulmonary delivery for therapeutic and other purposes may be prepared.|
|Inventor(s):||Platz; Robert M. (Half Moon Bay, CA), Brewer; Thomas K. (Walnut Creek, CA), Boardman; Terence D. (Palo Alto, CA)|
|Assignee:||Inhale Therapeutic Systems (San Carlos, CA)|
1. A method for preparing dispersible dry powders of biological macromolecules, said method consisting of: providing an evaporable liquid medium containing a predetermined
concentration of the macromolecule and excipients; atomizing the liquid medium under predetermined atomizing conditions; drying the droplets in a heated gas stream under drying conditions selected to form dispersible particles of the composite material
containing the biological macromolecules, said atomizing conditions in combination with said drying conditions being effective to produce particles comprising a rugosity of at least 2.0 as measured by air permeametry, a moisture content below 10% by
weight and a particle size of less than 10 microns; and collecting said particles.
2. A method as in claim 1 wherein the concentration of total solids in the liquid medium is less than 10% by weight.
3. A method as in claim 2 wherein the solids content is less than 5% by weight.
4. A method as in claim 1 wherein said atomizing conditions are selected to form droplets having an average size below 11 microns.
5. A method as in claim 1 wherein 90% of the mass of the dispersible powder consists of particles having a diameter within the range of 0.1 microns-7 microns.
6. A method as in claim 1 wherein 95% of the mass of the dispersible powder consists of particles having a diameter within the range of 0.4 microns-5 microns.
7. As method as in claim 1 wherein the droplets are flowed co-currently with the heated gas stream and wherein the gas stream has an inlet temperature above 90.degree. C.
8. A method as in claim 7 wherein the inlet temperature is within 120-200.degree. C.
9. A method as in claim 7 wherein the gas stream has an inlet temperature above 110.degree. C. and an outlet temperature above 50.degree. C.
10. A method as in claim 9 wherein the outlet temperature is within 60-80.degree. C.
11. A method as in claim 1 further comprising packaging at least some of the particles in a container after the collecting step, wherein the particles have not been size classified prior to packaging.
12. A method as in claim 11 wherein the particles are packaged in a unit dosage container.
13. A method as in claim 1 wherein the macromolecule is selected from the group consiting of calcitonin, erythropoietin, factor IX, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, growth hormone, insulin, interferon alpha, interferon beta, interferon gamma, interleukin-2, luteinizing hormone releasing hormone (LHRH), somatostatin, vasopresin analog, follicle stimulating formone (FSH), amylin, ciliary neurotrophic factor, growth relesing factor, insulinotropin, interleukin-1 recepetor antagonist, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor, nerve growth factor, parathyroid hormone, thymosin alpha-1, factor IIb/IIIa inhibitor, alpha-1 antitrypsin, anti-RSV antibody, deoxyribonuclease (DNase), bactericidal/permeability increasing protein (BPI), anti-CMV antibody, interleukin-1 receptor, and interleukin-1 receptor antagonist.
14. A method as in claim 1 wherein the particles comprise a rugosity measured by air permeametry in the range of 3 to 6.
15. A macromolecule composition prepared by the method of any of claims 1-4 and 5-14.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.